Lipocine Total Other Income Expense Net from 2010 to 2024

LPCN Stock  USD 4.54  0.09  2.02%   
Lipocine Total Other Income Expense Net yearly trend continues to be very stable with very little volatility. Total Other Income Expense Net is likely to grow to about 1.7 M this year. During the period from 2010 to 2024, Lipocine Total Other Income Expense Net quarterly data regression pattern had sample variance of 2.4 T and median of 0.00. View All Fundamentals
 
Total Other Income Expense Net  
First Reported
2011-12-31
Previous Quarter
224.4 K
Current Value
411.7 K
Quarterly Volatility
679.2 K
 
Yuan Drop
 
Covid
Check Lipocine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lipocine's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 5.8 M or Other Operating Expenses of 14.9 M, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 0.76 or Book Value Per Share of 3.67. Lipocine financial statements analysis is a perfect complement when working with Lipocine Valuation or Volatility modules.
  
Check out the analysis of Lipocine Correlation against competitors.
To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.

Latest Lipocine's Total Other Income Expense Net Growth Pattern

Below is the plot of the Total Other Income Expense Net of Lipocine over the last few years. It is Lipocine's Total Other Income Expense Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lipocine's overall financial position and show how it may be relating to other accounts over time.
Total Other Income Expense Net10 Years Trend
Pretty Stable
   Total Other Income Expense Net   
       Timeline  

Lipocine Total Other Income Expense Net Regression Statistics

Arithmetic Mean(297,991)
Geometric Mean0.00
Coefficient Of Variation(514.49)
Mean Deviation1,065,435
Median0.00
Standard Deviation1,533,138
Sample Variance2.4T
Range5.4M
R-Value0.11
Mean Square Error2.5T
R-Squared0.01
Significance0.69
Slope38,251
Total Sum of Squares32.9T

Lipocine Total Other Income Expense Net History

20241.7 M
20231.6 M
20221.4 M
2021-3.8 M
2020-3 M
2019-106.9 K
2018-333.5 K

About Lipocine Financial Statements

Lipocine investors utilize fundamental indicators, such as Total Other Income Expense Net, to predict how Lipocine Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Total Other Income Expense Net1.6 M1.7 M

Pair Trading with Lipocine

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipocine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipocine will appreciate offsetting losses from the drop in the long position's value.

Moving against Lipocine Stock

  0.66VRAX Virax Biolabs GroupPairCorr
  0.6FENC Fennec PharmaceuticalsPairCorr
  0.57VRCA Verrica PharmaceuticalsPairCorr
  0.54ELEV Elevation OncologyPairCorr
  0.53FATE Fate Therapeutics TrendingPairCorr
The ability to find closely correlated positions to Lipocine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipocine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipocine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipocine to buy it.
The correlation of Lipocine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipocine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipocine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lipocine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Lipocine offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipocine's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipocine Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipocine Stock:
Check out the analysis of Lipocine Correlation against competitors.
To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.75)
Revenue Per Share
0.903
Quarterly Revenue Growth
137.519
Return On Assets
(0.23)
Return On Equity
(0.34)
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.